Hackensack, NJ – BHI Therapeutic Sciences is pleased to announce that Brian Mehling, MD, Chief Medical Officer and Marina Manvelyan, Ph.D., Clinical Research Scientist have been accepted as members of the prestigious International Society for Stem Cell Research (ISSCR).
Members of the ISSCR have been sharing global stem cell science for more than 15 years. With roughly 4,000 members from more than 60 countries, the ISSCR is the pre-eminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The organization promotes global collaboration among the world’s most talented and committed stem cell scientists and physicians, and plays a catalyzing role in the development of effective new treatments.
According to George Q. Daley, MD, Ph.D., dean, Harvard Medical School and professor, Boston Children’s Hospital & Dana Farber Cancer Institute, “Core strengths of the ICCSR include its scientific integrity and excellence, and its outstanding membership comprised of research leaders worldwide.”
Dr. Mehling is the founder and chief medical officer of BHI Therapeutic Sciences. He is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.
“We are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added.
Dr. Mehling and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.
Dr. Manvelyan has 15 years of experience in biomedical research and is the author of more than 40 research papers.
She started her research career as a research scientist at Yerevan State University (Armenia) and University Hospital of Jena, Institute of Human Genetic (Germany).
As a Clinical Research Scientist at BHI Therapeutic Sciences, she is conducting scientific research and clinical investigations of adult stem cell therapy for various medical conditions.
The ISSCR promotes the highest scientific and ethical standards and is dedicated to integrity in the rigor and quality of the research community’s scientific work. BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells. Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com.